Company intelligence / Profile preview

Rarity Bioscience

Uppsala, Uppsala County, Swedenraritybioscience.com ↗

Ownership: Private
Development stage: Commercial

Overview

Rarity Bioscience has developed the superRCA platform, an ultrasensitive multiplexed molecular assay for detecting rare DNA sequence variants such as cancer mutations. The platform is 10–100 times more sensitive than current technologies and can detect one mutation among 100,000 wild-type sequences. It is designed for both research and clinical applications, especially liquid biopsy-based cancer diagnostics[1][3][4].

Therapeutic areas: OncologyHematology
Modalities: Diagnostic assayMolecular amplification technology (superRCA)
Industry: Molecular Diagnostics

Partnerships

Beckman Coulter Life Sciences (co-exclusive distribution agreement to market/distribute superRCA assays globally)[1]

Beyond the preview

Go deeper on Rarity Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rarity Bioscience.

Explore the full profile